Coherus Oncology (FRA:8C5) LT-Debt-to-Total-Asset: 0.14 (As of Mar. 2026)

What is Coherus Oncology LT-Debt-to-Total-Asset?

Coherus Oncology FRA:8C5 +7.47% 44 LT-Debt-to-Total-Asset is 0.14 as of Mar. 2026. GuruFocus rates FRA:8C5 with a GF Score™ of 44/100 and a GF Value™ of €0.62 (Significantly Overvalued). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Coherus Oncology's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.14.

Coherus Oncology's long-term debt to total assets ratio declined from Mar. 2025 (0.72) to Mar. 2026 (0.14). It may suggest that Coherus Oncology is progressively becoming less dependent on debt to grow their business.

Coherus Oncology (FRA:8C5) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Coherus Oncology LT-Debt-to-Total-Asset Related Terms

Coherus Oncology LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Coherus Oncology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coherus Oncology LT-Debt-to-Total-Asset Chart

Coherus Oncology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.61

0.99

0.76

0.60

0.15

Coherus Oncology Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.72	0.09	0.08	0.15	0.14

44GF Score

Coherus Oncology Inc FRA:8C5

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Coherus Oncology LT-Debt-to-Total-Asset Calculation

Coherus Oncology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	32.886	/	220.625
	=	0.15

Coherus Oncology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	32.957	/	230.109
	=	0.14

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.14 mean?

Coherus Oncology (FRA:8C5) has a LT-Debt-to-Total-Asset of 0.14 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Coherus Oncology and its competitors.

Is Coherus Oncology's LT-Debt-to-Total-Asset too high?

Coherus Oncology's current LT-Debt-to-Total-Asset is 0.14. Overall, Coherus Oncology has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Coherus Oncology's LT-Debt-to-Total-Asset compare to TARA and KPTI?

Coherus Oncology's LT-Debt-to-Total-Asset of 0.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current LT-Debt-to-Total-Asset is 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Coherus Oncology stock overvalued right now?

Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.62, compared to a current price of €1.44 — trading 131.9% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.14. Coherus Oncology's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current LT-Debt-to-Total-Asset is 0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coherus Oncology (FRA:8C5) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of €1.44 is trading 131.9% above its estimated GF Value™ of €0.62. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for FRA:8C5:

LT-Debt-to-Total-Asset: 0.14
GF Value™: €0.62 vs. price of €1.44 (131.9% above fair value)
GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Industry Healthcare Biotechnology

Comparable Companies TARA KPTI CNTN RNA QTTB AVXL SLGL CAMP CDXS KROS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges CHRS:USA

Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website https://www.coherus.com

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

44GF Score

Get the complete analysis for FRA:8C5

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.44

Price

€0.62

GF Value

View FRA:8C5 Analysis

See LT-Debt-to-Total-Asset data for all stocks →